FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of biotechnology and immunology. Claimed is isolated antibody (Ab7), which specifically binds with human glucagon receptor, containing heavy chain and light chain, variable regions of which contain amino acid sequences, presented in description as SEQ ID NO:12 and 28 respectively. Described is pharmaceutical composition for treatment of type II diabetes, which contains effective quantity of said antibody and one or several pharmaceutically acceptable carriers. In addition, disclosed are: isolated nucleic acid, which codes said antibody, and recombinant expression vector, which contains nucleic acid by claimed invention.
EFFECT: invention makes it possible to extend arsenal of medications which inhibit human glucagon receptor.
6 cl, 7 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF | 2018 |
|
RU2820628C2 |
| MEDICINAL AGENT CONTAINING PHOSPHOLIPASE D4 ANTIBODY | 2014 |
|
RU2709741C2 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO GD2 (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2796937C2 |
| ANTIBODIES CAPABLE OF BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2016 |
|
RU2727018C1 |
| ANTIBODIES TO CANINE INTERLEUKIN-4 ALPHA RECEPTOR | 2016 |
|
RU2736732C2 |
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| METHODS FOR TREATING FGF21-RELATED DISORDERS | 2016 |
|
RU2752530C2 |
| FGF21 MIMETIC ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2774368C2 |
